Investors focused on the Medical space have likely heard of Allergan plc , but is the stock performing well in comparison to the rest of its sector peers? Let's take a closer look at the stock's year-to-date performance to find out.

Allergan plc is one of 763 individual stocks in the Medical sector. Collectively, these companies sit at #10 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.

The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. AGN is currently sporting a Zacks Rank of #2 (Buy).

The Zacks Consensus Estimate for AGN's full-year earnings has moved 3.07% higher within the past quarter. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.

Our latest available data shows that AGN has returned about 1.92% since the start of the calendar year. In comparison, Medical companies have returned an average of 0.27%. As we can see, Allergan plc is performing better than its sector in the calendar year.

Looking more specifically, AGN belongs to the Medical - Generic Drugs industry, a group that includes 26 individual stocks and currently sits at #214 in the Zacks Industry Rank. On average, this group has gained an average of 1.04% so far this year, meaning that AGN is performing better in terms of year-to-date returns.

Investors with an interest in Medical stocks should continue to track AGN. The stock will be looking to continue its solid performance.